MedTrace Logo

A Phase 2 Study of PH-10 for the Treatment of Atopic Dermatitis

NCT00690807 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-09-28

No results posted yet for this study

Summary

PH-10 is a formulation of rose bengal disodium (RB) for topical administration to the skin. PH-10 is capable of undergoing photochemical reactions when activated by ambient light. This phase 2 study will assess whether topical PH-10 applied once daily to mild, moderate or severe areas of atopic dermatitis (including atopic eczema) may ameliorate inflammation of the skin when activated by ambient light.

Conditions

Interventions

DRUG

PH-10

PH-10 will be applied daily for 28 days to skin areas affected by atopic dermatitis.

Sponsors & Collaborators

  • Provectus Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Alicia Barba, MD · International Dermatology Research, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-08-31
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00690807 on ClinicalTrials.gov